2-(morpholin-4-yl)-1H-1,3-benzodiazol-5-amine | 832102-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(morpholin-4-yl)-1H-1,3-benzodiazol-5-amine
• 英文别名: 2-morpholin-4-yl-3H-benzimidazol-5-amine
• CAS: 832102-58-6
• 化学式: C₁₁H₁₄N₄O
• mdl: MFCD09881793
• 分子量: 218.258
• InChiKey: ATSINGARJSBJPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(morpholin-4-yl)-1H-1,3-benzodiazol-5-amine 、 methyl 5-(4-chlorophenyl)-3-{[(1E)-(dimethylamino)methylidene]amino}-2-thiophenecarboxylate 在 苯酚 作用下， 生成 6-(4-chlorophenyl)-3-(2-morpholin-4-yl-3H-benzimidazol-5-yl)thieno[3,2-d]pyrimidin-4-one
  参考文献：
  名称：

  Novel benzimidazole-based MCH R1 antagonists

  摘要：

  The identification of an MCH R1 antagonist screening hit led to the optimization of a class of benzimidazole-based MCH R1 antagonists. Structure-activity relationships and efforts to optimize pharmacokinetic properties are detailed along with the demonstration of the effectiveness of an MCH R1 antagonist in an animal model of obesity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.054
• 作为产物：
  描述：

  2-氯苯并咪唑 在 palladium on activated charcoal 硫酸 、 氢气 、 硝酸 作用下， 以 乙醇 为溶剂， 生成 2-(morpholin-4-yl)-1H-1,3-benzodiazol-5-amine
  参考文献：
  名称：

  Novel benzimidazole-based MCH R1 antagonists

  摘要：

  The identification of an MCH R1 antagonist screening hit led to the optimization of a class of benzimidazole-based MCH R1 antagonists. Structure-activity relationships and efforts to optimize pharmacokinetic properties are detailed along with the demonstration of the effectiveness of an MCH R1 antagonist in an animal model of obesity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.054

文献信息

• [EN] BICYCLIC HETEROCYCLES AS IRAK4 INHIBITORS<br/>[FR] HÉTÉROCYCLES BICYCLIQUES CONVENANT COMME INHIBITEURS DE L'IRAK4
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2013042137A1

  公开（公告）日：2013-03-28

  The present invention provides bicyclic heterocycle kinase enzyme inhibitor compounds of formula (I), which may be therapeutically useful as kinase inhibitor, more particularly IRAK4 inhibitors. ( I ) in which A, R, R1,R2, m, n and p have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly IRAK4 enzyme.The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了公式（I）的双环杂环化酶抑制剂化合物，可能在治疗中作为激酶抑制剂具有治疗作用，更具体地是IRAK4抑制剂。其中 A、R、R1、R2、m、n 和 p 的含义如规范中所给出，并且其在治疗和预防疾病或紊乱方面是有用的，特别是在需要抑制激酶酶有优势的疾病或紊乱中，更具体地是IRAK4酶的使用。本发明还提供了包含至少一种公式（I）的激酶抑制剂化合物的药物配方，以及其与药用载体、稀释剂或赋形剂一起使用。
• Identification of 2-aminobenzimidazoles as potent melanin-concentrating hormone 1-receptor (MCH1R) antagonists
  作者：Minoru Moriya、Hiroyuki Kishino、Shunji Sakuraba、Toshihiro Sakamoto、Takuya Suga、Hidekazu Takahashi、Takao Suzuki、Masahiko Ito、Junko Ito、Ryuichi Moriya、Norihiro Takenaga、Hisashi Iwaasa、Akane Ishihara、Akio Kanatani、Takehiro Fukami

  DOI：10.1016/j.bmcl.2009.04.147

  日期：2009.7

  A series of 2-aminobenzimidazole-based MCH1R antagonists was identified by core replacement of the aminoquinoline lead 1. Subsequent modi. cation of the 2- and 5-positions led to improvement in potency and intrinsic clearance. Compound 25 exhibited good plasma and brain exposure, and attenuated MCH induced food intake at 30 mg/kg PO in rats. (C) 2009 Elsevier Ltd. All rights reserved.
• [EN] HETEROCYCLIC MCHR1 ANTAGONISTS<br/>[FR] ANTAGONISTES HETEROCYCLIQUES DE MCHR1
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004092181A9

  公开（公告）日：2005-01-27

  [EN] This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines. Compounds of the invention have formula (I).
  [FR] L'invention concerne des dérivés de benzopyrane substitués, des stéréoisomères et des sels pharmaceutiquement acceptables desdits composés, ainsi que des procédés appropriés pour les préparer. Les composés de la présente invention s'utilisent comme agonistes du récepteur beta des oestrogènes. De tels agonistes s'utilisent dans le traitement d'affections induites par le récepteur beta des oestrogènes, telles que le cancer de la prostate ou l'hyperplasie prostatique bénigne (HPB).
• Novel benzimidazole-based MCH R1 antagonists
  作者：Andrew J. Carpenter、Kamal A. Al-Barazanji、Kevin K. Barvian、Michael J. Bishop、Christy S. Britt、Joel P. Cooper、Aaron S. Goetz、Mary K. Grizzle、Donald L. Hertzog、Diane M. Ignar、Ronda O. Morgan、Gregory E. Peckham、Jason D. Speake、Will R. Swain

  DOI：10.1016/j.bmcl.2006.07.054

  日期：2006.10

  The identification of an MCH R1 antagonist screening hit led to the optimization of a class of benzimidazole-based MCH R1 antagonists. Structure-activity relationships and efforts to optimize pharmacokinetic properties are detailed along with the demonstration of the effectiveness of an MCH R1 antagonist in an animal model of obesity. (c) 2006 Elsevier Ltd. All rights reserved.